UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Has $611,000 Stake in GoodRx Holdings, Inc. (NASDAQ:GDRX)

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lessened its position in shares of GoodRx Holdings, Inc. (NASDAQ:GDRX) by 49.4% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 88,021 shares of the company’s stock after selling 85,926 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC’s holdings in GoodRx were worth $611,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also made changes to their positions in GDRX. nVerses Capital LLC acquired a new position in GoodRx during the third quarter worth about $33,000. Plato Investment Management Ltd bought a new stake in shares of GoodRx during the second quarter worth about $43,000. Dark Forest Capital Management LP acquired a new position in GoodRx in the 2nd quarter valued at approximately $86,000. Quest Partners LLC bought a new position in shares of GoodRx during the third quarter valued at $160,000. Finally, Deerfield Management Company L.P. Series C acquired a new position in shares of GoodRx during the second quarter worth $173,000. Institutional investors and hedge funds own 63.77% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of analysts recently weighed in on GDRX shares. Citigroup decreased their price objective on GoodRx from $10.00 to $7.00 and set a “buy” rating for the company in a report on Wednesday, November 13th. Barclays lowered their price objective on GoodRx from $10.00 to $6.00 and set an “overweight” rating for the company in a research report on Monday, November 11th. Mizuho began coverage on GoodRx in a report on Wednesday, December 4th. They issued a “neutral” rating and a $5.00 target price on the stock. Finally, Morgan Stanley lowered their price target on shares of GoodRx from $7.00 to $6.00 and set an “equal weight” rating for the company in a report on Tuesday. One investment analyst has rated the stock with a sell rating, five have given a hold rating, nine have issued a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, GoodRx has an average rating of “Moderate Buy” and a consensus price target of $8.37.

GoodRx Stock Performance

Shares of GDRX opened at $4.44 on Friday. The stock has a 50-day moving average of $5.33 and a 200-day moving average of $6.97. GoodRx Holdings, Inc. has a one year low of $4.09 and a one year high of $9.26. The company has a debt-to-equity ratio of 0.70, a current ratio of 5.48 and a quick ratio of 5.48. The company has a market cap of $1.69 billion, a PE ratio of -148.00, a P/E/G ratio of 3.54 and a beta of 1.29.

GoodRx Company Profile

GoodRx Holdings, Inc, together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices.